Peripheral T-cell lymphoma - Not otherwise specified

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Critical reviews in oncology/hematology (Impact Factor: 4.03). 09/2011; 79(3):321-9. DOI: 10.1016/j.critrevonc.2010.07.007
Source: PubMed


Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) does correspond to a heterogeneous group of nodal and extranodal mature T-cell lymphomas, with a low prevalence in Western countries. PTCL-NOS accounts for about 25% of all PTCL, which represent over 15% of all lymphomas. In the lymph node, PTCL-NOS shows paracortical or diffuse infiltrates with effacement of the normal architecture, with a broad cytological spectrum and a frequently observed inflammatory background. Some morphological variants include: lymphoepithelioid or Lennert's type, T-zone, and follicular. PTCL-NOS is characterized by an aberrant T-cell phenotype, with frequent loss of CD5 and CD7. A CD4+/CD8- phenotype predominates in nodal cases. CD4/CD8 +/+ or -/- is at times seen, as is CD8, CD56 and cytotoxic granule expression. Ki-67 rate is typically high. TCR β-chain is usually expressed; TCR genes are most often clonally rearranged. PTCL-NOS typically occurs in adults (median age 55-60 years), with a higher prevalence in males. It presents more often as disseminated disease, occasionally with eosinophilia, pruritis or hemophagocytic syndrome. Patients often have B symptoms, generalized lymphadenopathy, bone marrow infiltration, and extranodal involvement, with high or high-intermediate IPI score in 50-70% of cases. Prognosis is poor, with a 5-year OS of 20-30%. Some variables, like ST2(L), CXCR5, CXCR3, EBV infection, cytotoxic granule expression, high proliferative index, NF-κB expression, were proposed as prognostic indicators, but the IPI score, and its variant called PIT, remains the most effective prognostic factor. Patients with PTCL-NOS should be treated with anthracycline-containing chemotherapy, followed by radiotherapy in cases of stage I-II disease. This strategy is associated with an overall response rate higher than 60%, but the 5-year overall survival is only 20-30%. Upfront high-dose chemotherapy supported by autologous or allogeneic SCT is an investigational approach, with a 4-year overall survival of about 40%. Patients with chemosensitive relapse respond favorably to high-dose chemotherapy and ASCT, with long-term survival rates of 35-45%. Graft-versus-lymphoma effect following allogeneic SCT has been observed; and reduced intensity conditioning emerges as an attractive strategy for frail patients. Most patients with PTCL-NOS are enrolled in prospective trials to explore new approaches, and new agents, like gemcitabine, alemtuzumab and pralatrexate, are being investigated.

Download full-text


Available from: Andrés José María Ferreri, Sep 08, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: We discuss the clinical presentation, investigations carried out, and the management issues in an elderly patient with hemophagocytic lymphohistiocytosis (HLH). The HLH was associated with an underlying Epstein-Barr virus positive peripheral T-cell lymphoma, not otherwise specified, and the lymphomatous cells harbored translocation t(5;9)(q11.2:p24). The 9p24 region contains the JAK2 gene. The disease had a fulminant course.
    Leukemia & lymphoma 03/2011; 52(6):1127-32. DOI:10.3109/10428194.2011.563888 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Periphere kutane T-Zell-Lymphome, deren morphologische und molekulare Variabilität keine weiterführende Klassifikation erlauben, werden innerhalb der Gruppe der primär kutanen peripheren T-Zell-Lymphome – nicht spezifiziert – (PCTL-NOS) zusammengefasst. Die PCTL-NOS stellen eine seltene, heterogene Gruppe dar, die sich in den meisten Fällen durch rasch auftretende Knoten ohne die für die Mycosis fungoides typischen Plaques, eine ungünstige Prognose und ein schlechtes Therapieansprechen auszeichnen. Wir berichten über einen 62-jährigen Patienten mit asymptomatischen Papeln im Bereich der Ellen- und Kniebeuge. Anhand histopathologischer Kriterien konnte die Diagnose eines PCTL-NOS gestellt werden. Vor dem Hintergrund von Genexpressionsstudien erhofft man sich ein Therapieansprechen auf Tyrosinkinase- und Histon-Deacetylaseinhibitoren. Peripheral cutaneous T-cell lymphoma which cannot be further classified due to high morphological and molecular variability are included into the group of “primary cutaneous peripheral T-cell lymphoma – not otherwise specified” (PCTL-NOS). PCTL-NOS represent a rare, heterogeneous group characterized by rapidly progressive nodules in the absence of typical mycosis fungoides plaques. Furthermore, therapeutic options are limited and prognosis is rather poor. We report on a 62-year-old patient presenting with asymptomatic papules in the popliteal and antecubital fossae. Based on histopathological criteria, PCTL-NOS was diagnosed. Based on recent gene expression studies, a positive reaction to tyrosine kinase and histone deacetylase inhibitors is hoped for. SchlüsselwörterT-Zell-Lymphom–Primär kutanes T-Zell-Lymphom–PCTL-NOS–Tyrosinkinaseinhibitoren–Histon-Deacetylaseinhibitoren KeywordsT-cell lymphoma–Primary cutaneous peripheral T-cell lymphoma–PCTL-NOS–Tyrosine kinase inhibitors–Histone deacetylase inhibitors
    Der Hautarzt 05/2011; 62(5):332-335. DOI:10.1007/s00105-011-2164-3 · 0.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nodal peripheral T-cell lymphomas (PTCLs) have particularly poor prognoses. Few data enabling establishment of an accepted standard treatment modality for PTCLs are available. We hypothesized that fludarabine-based regimens are tolerable and effective in treatment for nodal PTCLs. Therefore, this study was to analyze the toxicity of, response rate for, and outcome of treatment for nodal PTCLs with oral fludarabine, doxorubicin, and dexamethasone (FAD). Patients with PTCLs received FAD every 28 days, consisting of oral fludarabine at 40 mg/m(2) on days 1-3, doxorubicin at 50 mg/m(2) on day 1, and oral dexamethasone at 20 mg/day on days 1-5. Patients who did not exhibit disease progression received at least four courses of treatment. Thirty-one of 35 patients with previously untreated nodal PTCLs enrolled in the study from 2007 to 2008 were evaluable. The incidence of grade 3-4 neutropenia was 55%. Nine patients had to have dose reductions of fludarabine and doxorubicin, none of whom had grade 3 or 4 toxic effects at the lower dose. Five of 31 patients had pneumonitis. No treatment-related mortality occurred. The response rate for the entire patient population was 71%, and the complete remission rate was 48%. The PFS and OS rates at 2 years were 54.2 and 77.1%, respectively. Four patients had died of cancer progression at the time of this analysis. The serum lactate dehydrogenase level had a significant effect on PFS and OS. The FAD regimen had encouraging efficacy with an acceptable toxicity profile in patients with nodal PTCLs.
    Cancer Chemotherapy and Pharmacology 07/2011; 69(2):387-95. DOI:10.1007/s00280-011-1711-z · 2.77 Impact Factor
Show more